Foley SB, Rios JJ, Mgbemena VE, Robinson LS, Hampel HL, Toland AE, Durham L, and Ross TS. Use of whole genome sequencing for diagnosis and discovery in the cancer genetics clinic. EBioMedicine 2015; 2(1) 74-81.
Ross TS and Mgbemena VE. Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia. Molecular & Cellular Oncology 1(3) 2014 e963450.
Yorczyk A, Robinson LS and Ross TS. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clinical Genetics 2014 Oct 16. Epub ahead of print.
Messa M , Ruben Fernandez-Busnadiego R, Sun EW, Chen Hong, Czapla H, Wrasman K, Wu Y, Ko G, Ross TS, Wendland B and De Camilli P. Epsin deficiency impairs endocytosis by stalling the actin-dependent invagination of endocytic clathrin coated pits. Elife 2014 Aug 13: e03311.
Pritzlaff M, Yorczyk A, Robinson LS, Pirzadeh-Miller S, Lin T, Euhus D, and Ross TS. An internal performance assessment of CancerGene Connect: An electronic tool to streamline, measure and improve the entire genetic counseling process. Journal of Genetic Counseling 23(6): 1034-1044, 2014.
Phillips ST, Hildenbrand ZL, Oravecz-Wilson KI, Foley SB, Mgbemena VE and Ross TS. Towards a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. Oncogene, advance online publication 18 November 2013; doi: 10.1038/onc.2013.484.
Foley SB*, Hildenbrand ZL*, Soyombo AA, Magee JA, Wu Y, Oravecz-Wilson KI and Ross TS. Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. Cell Rep. 5(1):51-60, 2013.
Soyombo AA*, Wu Y*, Kolski L, Rios JJ, Rakheda D, Chen A, Kehler J, Hampel H, Coughran A and Ross TS. Analysis of induced pluripotent stem cells from a BRCA1 mutant family.Stem Cell Rep. 1(4): 336-349, 2013.
Ames HM*, Wang AA*, Coughran A, Evaul K, Huang S, Graves CW, Soyombo A and Ross TS. Huntingtin interacting protein 1 phosphorylation by receptor kinases. Mol. Cell. Biol. 33(18): 3580-3593, 2013.
Ames HM, Bichakjian CK, Liu GY, Oravecz-Wilson KI, Fullen DR, Verhaegen M, Johnson TM, Dlugosz, AA and Ross TS. Huntingtin interacting protein 1: a merkel cell carcinoma marker that Interacts with c-Kit. J. Invest. Derm. 131(10):2113-20, 2011.
Oravecz-Wilson KI*, Philips ST*, Yilmaz OH, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ and Ross TS. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell 16(2):137-48, 2009.
Graves CW*, Philips ST*, Bradley SV, Oravecz-Wilson KI, Li L, Gauvin A and Ross TS. Use of a cryptic slice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues. Cancer Res. 68(4):1064-73, 2008.
Bradley SV, Smith MR, Li L, Hyun TS, Lucas PC, Joshi I, Jin F, Antonuk D and Ross TS. Aberrant huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res. 67(18):8923-31, 2007.
Bradley SV*, Hyun TS*, Oravecz-Wilson KI, Li L, Waldorff E, Ermilov A, Goldstein S, Zhang CX, Drubin DG, Varela K, Parlow A, Dlugosz AA and Ross TS. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1. Hum. Mol. Genet. 16(11):1279-92, 2007.
Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS and Ross TS. Huntingtin interacting protein 1 Is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res. 67(8):3609-15, 2007.
Bradley SV, Oravecz-Wilson KI, Gougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Chinnaiyan AM, Corradetti MN, Sanda MG and Ross TS. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 65(10):4126-4133, 2005.
Hyun TS, Oravecz-Wilson KI, Li L, Munaco AJ, Provot MM, Mizukami IF and Ross TS. Hip1-related mutant mice grow and develop normally but have accelerated spinal abnormalities and dwarfism in the absence of HIP1. Mol. Cell. Biol. 24(10):4329-40, 2004.
Hyun TS and Ross TS. HIP1: Trafficking roles and regulation of tumorigenesis. Trends Mol. Med. 10(4):194-9, 2004.
Oravecz-Wilson KI , Kiel MJ, Rao DS, Saint-Dic D, Li L, Kumar PD, Provot MM, Bradley SV, Hankenson KD, Reddy VN, Lieberman AP, Morrison SJ, and Ross TS. Huntingtin interacting protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts. Hum. Mol. Gen. 13(8):851-67, 2004.
Hyun TS, Rao DS, Saint-Dic D, Michael E, Kumar PD, Bradley SV, Mizukami IF, Oravecz- Wilson KI, and Ross TS. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phoshoinositides via epsin N-terminal homology domains. J. Biol. Chem. 279(14):14294-306, 2004.
Rao DS*, Bradley SV*, Kumar PD, Hyun TS, Saint-dic D, Oravecz-Wilson KI, Kleer CG and Ross TS. Altered receptor trafficking in huntingtin interacting protein 1-transformed cells. Cancer Cell 3:471-482, 2003.
Rao D S, Hyun T S, Mizukami I, Rubin M, Lucas P and Ross TS. Huntingtin-interacting protein 1 is overexpressed in cancer cells and its ENTH domain is critical for cellular survival. J. Clin. Invest. 110(3):351-360, 2002.
Mishra SK, Agostinelli NR, Brett TJ, Mizukami I, Ross TS and Traub LM. Clathrin and AP-2 binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins. J. Biol. Chem. 276:46320-326, 2001.
Rao D., Chang JC, Kumar P, Mizukami I, Smithson GM, Bradley SV, Parlow AF and Ross TS. Huntingtin interacting protein 1 is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors. Mol. Cell. Biol. 21:7796-7806, 2001.
Saint-Dic J, Chang SC, Taylor GS, Provot MM and Ross TS. Regulation of the SH2-containing inositol 5-phoshatase SHIP1 in HIP1/PDGFbetaR transformed cells. J. Biol. Chem. 276:21192-198, 2001.
Ross TS, Gilliland DG. Transforming properties of the huntingtin interacting protein 1/ platelet-derived growth factor β receptor fusion protein J. Biol. Chem. 274:22328-22336, 1999.
Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of huntingtin interacting protein 1 to PDGFβR in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91:4419-4426, 1998.